Impactful Policy Action to Reduce Drug Costs in Managing Critically Ill Patients with COVID-19

Tichy, Eric M.; Francis, James R.

doi:10.1016/j.mayocp.2020.06.042

Cited by 1 publication

(1 citation statement)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 The ending of the Unapproved Drug Initiative will end the practice of older drugs receiving new patent protection, which over the past decade has led to the massive expenditure increases for old drugs such as epinephrine and vasopressin; the former is still a top 25 drug in overall expenditures, and the latter is in the top 10 by expenditures in the nonfederal hospital sector. 21 , 22 …”

Section: Discussionmentioning

confidence: 99%

National trends in prescription drug expenditures and projections for 2021

Tichy

Hoffman

Suda

et al. 2021

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.

show abstract

Section: Discussionmentioning

confidence: 99%